As of May 29, 2025, Millennium Pharmacon International Tbk PT (SDPC.JK) reports a Gross Margin of 8.54%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Millennium Pharmacon International Tbk PT's Gross Margin
Over recent years, Millennium Pharmacon International Tbk PT's Gross Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 8.54% |
| 2023-12-31 | 8.69% |
| 2022-12-31 | 8.42% |
| 2021-12-31 | 8.09% |
| 2020-12-31 | 8.39% |
This slight downward trend highlights how Millennium Pharmacon International Tbk PT manages its operational efficiency and pricing power over time.
Comparing Millennium Pharmacon International Tbk PT's Gross Margin to Peers
To better understand Millennium Pharmacon International Tbk PT's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Millennium Pharmacon International Tbk PT (SDPC.JK) | 8.54% |
| Quantum Health Group Ltd (QTM.AX) | 52.12% |
| Grand Brilliance Group Holdings Ltd (8372.HK) | 51.21% |
| Wonik Co Ltd (032940.KQ) | 49.28% |
| Balaxi Pharmaceuticals Ltd (BALAXI.NS) | 46.67% |
| Shanghai Pioneer Holding Ltd (1345.HK) | 44.62% |
Compared to its competitors, Millennium Pharmacon International Tbk PT's Gross Margin is among the lowest compared to peers, suggesting potential challenges in production costs or pricing strategy.